Last reviewed · How we verify

Nicotine replacement therapy - nicotine gum

Iowa City Veterans Affairs Medical Center · Phase 3 active Small molecule

Nicotine gum delivers nicotine through the oral mucosa to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation.

Nicotine gum delivers nicotine through the oral mucosa to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation. Used for Nicotine dependence / smoking cessation.

At a glance

Generic nameNicotine replacement therapy - nicotine gum
Also known asNicotine polacrilix, Nicotine gum
SponsorIowa City Veterans Affairs Medical Center
Drug classNicotinic acetylcholine receptor agonist
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaAddiction Medicine / Smoking Cessation
PhasePhase 3

Mechanism of action

Nicotine acts as an agonist at nicotinic acetylcholine receptors, particularly in the mesolimbic dopamine pathway, which mediates reward and addiction. By providing exogenous nicotine without the harmful combustion byproducts of cigarettes, the gum reduces the severity of withdrawal symptoms and cravings, facilitating abstinence. The gradual tapering of nicotine dose allows patients to progressively reduce dependence.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: